

## Medical Policy:

### Cytogam® (cytomegalovirus immune globulin, human) Intravenous

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.139	March 20, 2024	

**Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.**

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

## Definition

Cytogam is an injectable product that contains antibodies directed specificial cytomegalovirus (CMV), which is generally present in persons who have been exposed to the virus. While CMV in adults is typically benign in healthy people, it is a significant cause of morbidity and mortality in people who are immunosuppressed due to organ transplantation or AIDS. Cytomegalovirus Immune Globulin IV is currently approved by the Food and Drug Administration (FDA) for use in attentuation of CMV disease in renal transplant patients. It also has been shown to be beneficial in prevention and CMV disease in patients who have received an orthotopic liver transplant. There is also evidence for use of CMV organ transplants (such as heart and lung) and in bone marrow transplants.

## Length of Authorization

Coverage will be provided for 12 months.

## Guideline

### I. Initial Approval Criteria

***Cytogam*** may be considered medically necessary if one of the below conditions are met **AND** use is consistent

with the medical necessity criteria that follows:

1. **Cytomegalovirus infection, Prophylaxis – Transplantation of any of the following;**
  - A. Kidney
  - B. Lung
  - C. Liver
  - D. Pancreas
  - E. Heart

### Limitations/Exclusions

Cytogam is not considered medically necessary for when any of the following selection criteria is met:

1. Persons with selective IgA deficiency with antibodies to IgA **AND** a history of anaphylactic reactions to human immune globulin preparations.
2. History of prior severe reaction associated with the administration of Cytogam or any other human immunoglobulin preparations.

### II. Renewal Criteria

1. Patient continues to meet INITIAL APPROVAL CRITERIA.

### Dosage/Administration

Indication	Dose
Cytomegalovirus infection; Prophylaxis - Transplant of kidney	150 mg/kg IV for 1 dose within 72 hours of transplant then 100 mg/kg on weeks 2,4,6, and 8 post transplant and 50 mg/kg on weeks 12 and 16 post transplant
Cytomegalovirus infection; Prophylaxis - Transplant of Lung	150 mg/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg/kg on weeks 12 and 16 post transplant
Cytomegalovirus infection; Prophylaxis - Transplant of Liver	150 mg/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg/kg on weeks 12 and 16 post transplant
Cytomegalovirus infection; Prophylaxis - Transplant of Pancreas	150 mg/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg/kg on weeks 12 and 16 post transplant
Cytomegalovirus infection; Prophylaxis - Transplant of Heart	150 mg/kg IV within 72 hours of transplant and on weeks 2,4,6, and 8 post transplant and 100 mg/kg on weeks 12 and 16 post transplant

### Applicable Procedure Codes

Code	Description
J0850	Injection, cytomegalovirus immune globulin intravenous (human), 1 billable unit = per vial
90291	Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use

### Applicable NDCs

Code	Description
44206-0532-xx	Cytogam 50mg/mL single use vial

### ICD-10 Diagnoses

Code	Description
------	-------------

B25.0	Cytomegaloviral pneumonitis
B25.1	Cytomegaloviral hepatitis
B25.2	Cytomegaloviral pancreatitis
P35.1	Congenital cytomegalovirus infection
T86.1	Complications of kidney transplant
T86.10	Unspecified complication of kidney transplant
T86.11	Kidney transplant rejection
T86.12	Kidney transplant failure
T86.13	Kidney transplant infection
T86.19	Other complication of kidney transplant
T86.2	Complications of heart transplant
T86.20	Unspecified complication of heart transplant
T86.21	Heart transplant rejection
T86.22	Heart transplant failure
T86.23	Heart transplant infection
T86.29	Other complications of heart transplant
T86.298	Other complications of heart transplant
T86.30	Unspecified complication of heart-lung transplant
T86.31	Heart-lung transplant rejection
T86.32	Heart-lung transplant failure
T86.33	Heart-lung transplant infection
T86.39	Other complications of heart-lung transplant
T86.4	Complications of liver transplant
T86.40	Unspecified complication of liver transplant
T86.41	Liver transplant rejection
T86.42	Liver transplant failure
T86.43	Liver transplant infection
T86.49	Other complications of liver transplant
T86.81	Complications of lung transplant
T86.810	Lung transplant rejection
T86.811	Lung transplant failure
T86.812	Lung transplant infection
T86.818	Other complications of lung transplant
T86.819	Unspecified complication of lung transplant
T86.89	Complications of other transplanted tissue
T86.890	Other transplanted tissue rejection
T86.891	Other transplanted tissue failure
T86.892	Other transplanted tissue infection
T86.898	Other complications of other transplanted tissue
T86.899	Unspecified complication of other transplanted tissue
T86.9	Complication of unspecified transplanted organ and tissue
T86.90	Unsp complication of unspecified transplanted organ and tissue
T86.91	Unspecified transplanted organ and tissue rejection
T86.92	Unspecified transplanted organ and tissue failure
T86.93	Unspecified transplanted organ and tissue failure
T86.99	Other complications of unspecified transplanted organ and tissue

Z29.1	Encounter for prophylactic immunotherapy
Z29.8	Encounter for other specified prophylactic measures
Z29.9	Encounter for prophylactic measures, unspecified
Z48.2	Encounter for aftercare following organ transplant
Z48.21	Encounter for aftercare following heart transplant
Z48.22	Encounter for aftercare following kidney transplant
Z48.23	Encounter for aftercare following liver transplant
Z48.24	Encounter for aftercare following lung transplant
Z48.28	Encounter for aftercare following multiple organ transplant
Z48.280	Encounter for aftercare following heart-lung transplant
Z48.288	Encounter for aftercare following multiple organ transplant
Z94.0	Kidney transplant status
Z94.1	Heart transplant status
Z94.2	Lung transplant status
Z94.3	Heart and lungs transplant status
Z94.4	Liver transplant status
Z94.83	Pancreas transplant status

## Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	3/20/2024	Annual Review: added 90291, updated NDC
EmblemHealth & ConnectiCare	7/18/2023	Annual Review: No Criteria Changes
EmblemHealth & ConnectiCare	4/11/2022	Transferred policy to new template
EmblemHealth & ConnectiCare	7/15/2019	Annual review

## References

1. Product Information: CYTOGAM® IV injection, cytomegalovirus immune globulin (human) IV injection. MedImmune, Inc, Gaithersburg, MD, 2004.